It targets multiple pathways underlying a migraine attack ... The latest FDA nod for Symbravo diversifies Axsome’s commercial drug portfolio. The company currently markets Auvelity (AXS-05 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback